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Nucleic acid vaccinations with plasmids p\VW65, containing the sequence for herpes simplex 
type 2 (HSV-2) gD2. and pRSVnt, lacking the gO sequence, were studied. Groups of mice were 
immunized with pWW65 alone, pWW65 plus 1,2S.dihydroxyvitamin-D3 (D3), or pRSVnt. CHnical 
disease (vaginitis), serum and vaginal washing antibody levels, and vaginal washing virus titers 
were measured after intravaginal HSV-2 chaJlenge. No animals (0110) in the pWW65 + D3 group, 
6110 animals in the pWW6S group, and 10110 anima1s in the pRSVnt group developed severe disease 
by postchallenge day 13 (P < .001, P = ,04 vs. pRSVnt). Virus titers in vaginal washings were 
significantly reduced in the pWW6S and pWW65 + 03 groups versus the pRSVnt group (P < 
.001). Increasing levels of serum anti-g02 antibodies were measured 2 and 6 days after challenge 
among animals in the pWW65 and pWW65 + 03 groups but not among animals in the pRSYnt 
group. Vaccinations with a plasmid containing the 802 gene are immunogenic and provide some 
protection from HSY-2-induced disease. 
Wolff and colleagues [1, 2] were the first to show that direct 
transfection of murine muscle is a feasible way to transfer 
exogenous genes in vivo. This technique has been used to show 
immunogenicity of a human immunodeficiency virus (HIV) 
plasmid construct inoculated repeatedly into mice and monkeys 
[3,4]. Inoculation of "naked DNA" into living tissues and 
the-resulting expression of encoded exogenous proteins offers 
the theoretical benefit of antigen presentation in the context of 
class I major histocompatibility complex (MHC) molecules, 
potentially resulting in the generation of a powerful cell-medi· 
ated immune response [5]. Recent reports have described the 
use of nucleic acid vaccination to protect from influenza virus 
challenge in mice and chickens [6-9]. 
Herpes simplex virus type 2 (HSV-2) gD is an important 
herpes envelope glycoprotein involved in attachment and pene-
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tration of the virus into host cells. Investigations of the natural 
immune response to HSV-2 infection in humans reveal that 
serum antibodies against gO develop in all patients by 6-12 
months after primary infection [IOJ. Cervical antibodies to gO 
develop even faster, appearing within 2 weeks of primary HSV-
2 infection [11]. T cells that respond specifically to gD have 
been isolated from HSV -infected mice and from a lesion in 1 
human with recurrent genital herpes [12, 13]. Passive immuni-
zation with monoclonal antibodies directed against gD protects 
mice from live HSV challenge [14, 15J. HSV subunit vaccines 
containing gD2 have recently been studied for the prevention 
of genital herpes in anima1 models and in humans [16, 17J 
We were interested in studying whether a DNA plasmid encod-
ing gD2 might a1so confer immunity in the murine vaginitis 
model of genital herpes. 
Topical 1,25-dihydroxyvitamin-D3 (03) administered to ro-
dents changes the profile of cytokines elicited from underlying 
lymphoid tissue [18, 191. Topical and intramuscular administra-
tion of this compound as an adjuvant to protein immunogens 
in mice resulted in enhanced serum and mucosal immune re-
sponses. We hypothesized that incorporation of D3 might en-
hance the proposed immunogenicity of an existing plasmW 
containing the sequence for HSV -2 gO [20]. The present exper-
iments sought evidence that immunizations with a plasmid con· 
struct (PWW65) containing a Rous sarcoma virus promoter 
and the sequence for g02 are immunogenic and provide some 
protection from severe disease due to HSV·2 infection in the 
murine vaginitis model. 
Materials and Methods 
Animals. BALB/c mice (female, 6-8 weeks old; Sasco, Wi1· 
mington, MA) were used in all groups. 
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Jlirus and cultures. HSV -2 strain MS originally obtained from 
6. Kern (Department of Medicine, University of Alabama at Bir-
mingham) was grown in mink lung cells, aliquoled, and stored at 
_10°C until ready for use in challenge experiments. Quantitative 
viral cultures were obtained from the mice 1, 2, 4, and 6 days 
after challenge by vaginal washing with 50 ~L of PBS and mixing 
iJlto 500 J.tL of Eagle MEM. To avoid disrupting the genital epithe-
liuID before viral challenge, vaginal washing specimens (for 
ELISA) were not taken before challenge but were delayed until 
postchallenge day I. Vaginal washing virus titers were obtained 
usiJlg plaque QSSQys on Vero cells. 
Vaccine preparation. Plasmids pWW65 and pRSVnt have 
been described [20). pWW65 contains the HSV-2 gO gene ex-
pressed under the control of a Rous sarcoma virus promoter. 
pRSVnt lacks the SD2 sequence but othetWise is identical to 
pWW65. The plasmids were amplified using transfonned Esche~ 
richia coli DH5a and purified using Wizard Megapreps (Promega, 
Madison, Wl) to a concentration of 1.0 mg of DNAlmL. 
Vaccinations. Preliminary experiments were done with a sin-
gle intramuscular immunization in the left thigh with 3-100 J.tg 
ofpWW65 or pRSVnt, followed by live viral challenge 6 weeks 
later. No alum and no proteins were included in the vaccine. In 
!be subsequent study of multiple nucleic acid vaccinations, 10 mice 
~ived pWW65 alone 2, 3, and 4 weeks before challenge; 10 
received pWW65 and 0.1 p.g ofm (gift of Hoffman-La Roche, 
Nutley, NJ) 4 weeks before challenge, then pWW65 alone 2 and 
3 weeks before challenge (pWW65 + m group); and 10 mice 
[Keived pRSVnt alone 2, 3, and 4 weeks before challenge. 
Pretreatment and inoculation. Preliminary experiments were 
done using concentrated virus (6.3 X 106 pfulmL) without me-
droxyprogesterone pretreatment. To synchronize the estrus cycle 
in the mice and produce uniform susceptibility to HSV-2 challenge, 
!be animals were treated with subcutaneous medroxyprogesterone 
(Depo-Provera; Upjohn, Kalamazoo, MI) 4 days before challenge 
{211. Microscopic examination of vaginal washings 3 days after 
medroxyprogesterone injection confirmed that all 30 animals were 
in the diestrus phase of the menstrual cycle. Mice were anesthe-
tized before inoculation with 2.0 mg of intraperitoneal ketamine. 
About 100 p.L of virus suspension was adsorbed onto Dacron 
pledgets and placed in the vagina for 30 min. 
Assessment of vaginitis. Mice were scored daily by an un-
blinded observer for the severity of external genital inflammation 
(0 : no vaginitis, 1 .: mild swelling or redness, 2 == moderate 
swelling or erosions, and 3 = severe genital maceration) [22]. 
Animals were defined as having "severe disease" if they devel-
oped urinary retention or hind limb paralysis at any time or external 
genital maceration on 2 consecutive days. Such animals were 
promptly sacrificed. 
Serology. Neutralizing antibodies were detennined on 96-well 
pjates as described [23]. Briefly, }:20 initial serum dilutions, run 
in quadruplicate, were serially diluted 1:2 and incubated with 24 
pfu of HSV-2 at 37"C for 60 min. Vera cells (104) were added 
and incubated at 37°C for 5 days. Neutralizing titers are expressed 
lIS the inverse of the highest dilution at which no cytopathic effect 
\¥as detected. Ninety-six-well plates were prepared for ELISA by 
tooting with 3 J.tglmL baculovirus-expressed (for serum detennina-
lions) or purified (for vaginal washing detenninations) gD2. Non-
Specific binding was prevented by incubating the plates for 2 h at 
3rc with a solution of 10% nonnal goat serum and 0.4% Tween 
in PBS (NGSlTweenfPBS). Serial 1:2 dilutions of clinical samples 
in NGSffweenIPBS were done starting at an initial dilution of 
1:100 for vaginal washings and 1:1000 for serum. Binding of anti-
gD2 antibodies was detected by incubating the serum dilutions 
for 90 min at 3'FC with goat anti-IgG, olgA, or -igM antiserum 
(pharmigen, San Diego) tagged with horseradish peroxidase, de-
veloping with chromogen substrate, and reading optical densities 
(ODs) at 405 om. Log-transfonned ODs were plotted against log-
transformed dilutions, and linear regression analysis was used to 
detennine end-point titers. End points were designattd as 3-fold 
over binding observed from control mouse sera. 
Statistical analysis. Development of severe disease was com-
pared between groups using Fisher's exact and the X2 tests for 
discrete data. Clinical severity scores through day 8 and HSV titers 
from vaginal secretions through day 6 were compared by area 
under the curve (AUC) analysis using tbe MalUl-Whitney test {24]. 
Serum, vaginal washing, and neutralizing antibody titers were 
compared using the Mann-Whitney or Kruskal-Wallis test. P val-
ues expressed are two-tailed. 
Results 
Preliminary experiments using single 30- to I OO-p,g pWW65 
immunizations at least 4 weeks before live viral challenge re-
sulted in partial protection from HSV-2-induced disease (data 
not shown). In an attempt to enhance irrununity, groups of 10 
animals were given three vaccinations at weekly intetvals with 
100 p,g ofpRSVnt or pWW65. A third group received 100 f-lg 
ofpWW65 + 0.1 p.g of 03 with the first vaccination and 100 
p,g of p'NV/65 alone with the subsequent two vaccinations 
(pWW65 + D3 group). Pretreatment of the animals with me-
droxyprogesterone allowed genital infection to occur in all 
animals, based on vaginal washing viral cultures I and 2 days 
after challenge. The viral inoculum (5.3 X 105 pfulmL) follow-
ing medroxyprogesterone pretreatment was less than that used 
in previous experiments but produced severe infection in all 
10 nonimmune animals (data not shown). 
All 10 animals immunized with pRSVnt developed severe 
disease, requiring sacrifice by day 8 (figure I). Six of 10 ani-
mals immunized with pWW65 developed severe disease by 
day 14 (P = .04 vs. pRSVnt group). No animals immunized 
with pWW65 + D3 developed severe disease by day 13 (P < 
.001 vs. pRSVnt group). Animals immunized with pWW65 or 
pWW65 + D3 had much lower vaginitis AVe scores than 
those given pRSVnt (P < .001, data not shown). The pWW65 
+ D3 group showed a trend toward lower vaginitis Aue scores 
than the pWW65 group (P = .08). Animals in the pWW65 
and pWW65 + D3 groups had significantly lower vaginal 
washing virus titers (AVe scores) than those in the pRSVnt 
group (P < .001, both comparisons; figure 2). No difference 
in vaginal washing virus titers was detected between the 
pWW65 and pWW65 + D3 groups. 
Low levels of anti-gD2 IgG antibodies were detected in the 
prechaUenge serum of a few of the animals that received 
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pWW65 or pWW65 + D3 (figure 3). Rising levels of anti-
gD2 JgG antibodies were detected 2 and 6 days after viral 
challenge in the serum of these animals. No anti-gD2 antibodies 
were detected in serum samples from the pRSVnt group at any 
time. Anti-gD2 antibodies also were detected by ELISA in 
vaginal washings from pWW65 and pWW65 + 03 animals 
on postchallenge days 1 and 6 (figure 4). No anti-gD2 antibod-
ies were detected by ELISA in vaginal washings from pRSVnt 
animals at these time points. Both senuIl and vaginal antibody 
responses appeared to be exclusively IgG, with predominance 
of IgOI and IgGZa. No significant IgA or IgM production has 
been observed following immunization with these plasmids. 
Significant serum neutralizing activity was not detected in 
any of the groups before intravaginal viral challenge. Animals 
1000000 
f3 pWW6S 
in the pWW65 and pWW65 + 03 groups had detectable serum 
neutralizing activity 6 days after challenge (geometric mean 
titers [GMTs], 1:31 and 1:27, respectively). Serum from ani. 
mals that received pRSVnt did not have detectable neutralizing 
activity (P < .001 vs. the other groups). Quantitative ELISA 
(figure 4) and neutralizing antibody titers were similar between 
the pWW65 and pWW65 + D3 groups. Among the 10 animals 
that received only pWW65, levels of serum anti-gO and neu. 
tralizing antibodies did not correlate with protection from se-
vere disease. However, vaginal washing antibody levels were 
lower in the animals that developed severe disease (n = 6) 
than in those that were protected (n = 4) at postchallenge day 
1 (GMT == 1.75 vs. 3.49, P = .02) and day 6 (GMT = 2.41 






Figure 2. Poslchallenge geometric mean vaginal 
washing virus titers by vaccine group and time after 
live viral challenge. Vaginal washing virus titer iIlea 
under the curve (AUC) values (see Materials and 
Methods) for animals that were immunized witb 
pRSVnt were significantly higher than for those thai 
received either pWW65 or pWW65 + vitamin D3(P 
< .(01). No difference in virus titer AVe was de· 
tected between the pWW65 and pWW65 + OJ 
groups. 
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Figllre 3. Serum geometric mean an-
ribOdy titers (GMTs) against HSV-2 gD 
before and 2 and 6 days after challenge. 
Antibody levels were measured by 
ELISA. There was no difference be- ~ 
rNeeti groups before challenge (P = ~ 
.10). Animals immunized with pRSVnt "" 
bad undetectable levels «3 ELISA U) ! 
of serum antibodies at each time point, 
significantly lower vs. other 2 groups at 




Senun antibody levels from pWW65 
and pWW65 + vitamin D3 groups were 
not significantly different at any mea-
sured time point 
Prec:hallenge Day 2 Day" 
Perigenitai ulcerations appeared 7 -II days after cha1lenge 
in I of 4 animals that received pWW6S alone and in 6 of 10 
animals that received pWW65 + D3 (P not significant). Swab 
and tissue cultures for HSV taken from these lesions on post-
cballenge day 13 were negative. Histologic sections taken from 
3 representative erosions showed skin necrosis with a mixed 
subcutaneoUs infiltrate that included neutrophils and lympho-
cytes. Three of the 4 remaining perigenital erosions healed 
completely in 2-4 weeks, and 1 animal died of an unknown 
cause. 
Discussion 
In this study, three immunizations with a DNA vaccine en-
coding HSV -2 glycoprotein D provided partial protection from 
the development of severe disease in the murine vaginitis 
model. pWW6S-vaccinated animals had lower virus titers from 
vaginal secretions and produced gD2-specific serum antibodies 
Figure 4. Vaginal washing geometric mean 
antibody titers (GMTs) against HSV-2 gO on 
days 1 and 6 after challenge. Animals immu-
nized with pRSVnt had undetectable levels of 
vaginal washing antibodies at both time points, 
significantly lower vs. other 2 groups (P < 
.(01). Vaginal washing antibody levels among 
IDimals in pWW65 and pWW65 + vitamin OJ 
groups were not significantly different at either 
time point. Measured levels of vaginal washing 
lIltibOOies within each group did not change 
significantly between postchallenge days \ and 
6 (i.e., there was no significant rise or fall 




and serum HSV-2 neutralizing antibodies after challenge. 
pRSVnt-vaccinated (control) animals did not produce measur-
able antibody in serum or vaginal secretions and rapidly devel-
oped severe disease due to HSV-2 infection. Addition of a 
single injection of 0.1 }J-g of vitamin D3 at the beginning of 
the vaccination series appeared to enhance protection from 
severe disease but did not significantly enhance levels of anti-
bodies in serum or vaginal washings. 
Humoral immune responses to gD (protein) have been asso-
ciated with prevention of disease [15, 24, 25]. We believe that 
contamination of our plasmid preparations with gD2 cannot 
account for the immunogenicity ofpWW6S. The Rous sarcoma 
virus promoter included in pWW65 and pRSVnt is active only 
in eukaryotic systems, making production of gD2 theoretically 
impossible during plasmid replication in bacteria. We have 
shown that after precipitation of DNA in cold ethanol, no de-
tectable protein is left in our plasmid preparations. Western 
blotting has also failed to detect gD2 in our nucleic acid vaccine 
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preparations. We infer, on the basis of the presence of gD2-
specific antibodies exclusively in the pWW65-vacciIl{lted ani-
mals, that plasmid transfection of murine cells and expression 
of gD2 occurred in our system. 
No significant serum antibody activity was detected before 
challenge by either ELISA or neutralization techniques. Al-
though we cannot exclude the presence of low levels of anti-gO 
antibodies in the prechallenge sera, the rapid rise in detectable 
antibodies after challenge suggests that immunologic memory 
was induced by pWW65 vaccinations. The lack of detectable 
serum neutralizing activity or anti-gD antibodies in the pRSVnt 
controls at postchaJlenge day 6 is not surprising, as these ani-
mals developed severe disease and were sacrificed by day 8. 
This was probably too soon for a humoral immune response 
to primary HSV-2 infection to be measured. 
A different pattern of vaginal washing antibody activity was 
obselVed, in which somewhat lower, more stable levels of 
antibodies were measured (figure 4). Transudation of serum 
antibodies or low-level production and secretion of antibodies 
by the vaginal mucosa may account for this observation. A 
subanalysis of to animals that received only pWW65 showed 
that those producing higher levels of vaginal antibodies were 
more likely to be protected from severe disease, suggesting a 
protective role of vaginal washing antibodies in this system, 
whatever their origin. We did not detect IgA or IgM in vaginal 
secretions or serum following vaccinations withpWW65. Other 
groups investigating nucleic acid vaccines have also detected 
primarily IgG and low or undetectable levels of IgM and 19A 
[4, 6, 9, 26J. 
The mechanism of protection resulting from immunizations 
with pWW65 includes humoral and likely cellular immune 
responses. Plasmid immunization in other animal systems has 
resulted in cytotoxic lymphocyte responses to HIV [4, 26], 
influenza virus [6, 27], and Plasmodium species [2S]. Rouse 
et a!. (29] have shown that antigen-presenting cells transfected 
with DNA encoding for HSV -specific proteins generate anti-
gen-specific CDS cytotoxic lymphocytes. These findings by 
other groups provide support for the hypothesis that nucleic 
immunization results in transfection of host cells, transcription 
of foreign DNA, production of the antigen within host cells, 
and HSV antigen presentation to T lymphocytes in the context 
ofMHC class I. The presence of serum antibodies in our experi-
ments suggests that antigen-presenting cells, CD4 T lympho-
cytes, and B lymphocytes are involved in the induced immune 
response to pWW65. The detection of anti-gD2 antibodies also 
suggests presentation of gD2 antigen in the context of MHC 
class II in our system. 
Vitamin D3 dramatically enhances mucosal inunune re~ 
sponses to protein antigens [181 and contrasts with the prevail~ 
ing view that this compound is an inununosuppressive agent 
[30]. The mechanism of 03 enhancement of immunity in these 
systems is not completely understood but may relate to en-
hancement of a Th2 immune response via locally increased 
interleukin (IL)~4, IL-5, and IL-IO production [18, 19]. We did 
not find enhancement of senun or vaginal antibody level 
among the pWW65 + D3 animals compared with the PWW6S~ 
alone group. However, the groups were relatively small and 
the animals were given 03 only once during the immunization 
regimen. It is con.ceivable that using larger groups, D3 with 
each inununization, or a different dose of 03 might enhance 
antibody levels in the serum or at mucosal surfaces. Work to 
clarify this is in progress. 
Addition of D3 to the pWW65 vaccination schedule ap_ 
peared to have a beneficial effect on the course of HSV-2~ 
induced disease in this system. We consider this to be a prelimi_ 
nary observation, which needs to be carefully confirmed USing 
larger groups. We have considered the possibility that D3 may 
not have acted as an immunomodulator but could have had a 
direct effect on the host target epithelium, rendering it less 
susceptible to HSV-2 infection. However, we believe that DJ 
given along with a plasmid vaccination 4 weeks earlier is un-
likely to be active at the time of challenge [31], and subsequent 
experiments have shown that addition of D3 to the control 
vaccine does not provide protection from vaginitis or severe 
disease in our system. 
The presence of perigenital ulceration in some animals that 
were vaccinated and survived challenge may be related to a 
vigorous local cellular immune response or persistent viral 
replication (or both). Negative viral cultures and histologic 
sections support the hypothesis that these lesions are the result 
of a vigorous local immune response. More work is needed to 
characterize the cells contained in these inflammatory infiltrates 
and to determine whether very low levels of virus or viral 
antigens might be persisting within the lesions. 
In summary, the nucleic acid vaccine encoding g02 was 
immunogenic and attenuated HSV-2-induced vaginitis in a 
murine model. This approach offers a theoretical benefit over 
vaccination with proteins, because transfection of muscle with 
plasmid DNA may result in both MHC class I and II presenta-
tion of antigen, resulting in a broader, perhaps more effective 
immune response. Future studies may include vaccination .... ilh 
new plasmid constructs containing more than one HSV-2 gene, 
examining the efficacy of this vaccine in animal models of 
recurrent herpes, and measuring cellular imml.llle responses 
following nucleic acid vaccinations against HSV. 
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